Emily Bergsland • UCSF Profiles (original) (raw)

  1. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management. Insights Imaging. 2026 Feb 09; 17(1):37. Choucair A, Zdunek A, Liao M, Bodei L, Deandreis D, Das J, Barbe R, Bergsland E, Geyer S, Bidault F, Garcia G, Yeh R, Balleyguier C, Lassau N, Dercle L, Ammari S. PMID: 41661399; PMCID: PMC12886687.
    View in: PubMed Mentions:
  2. Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy. Endocr Pathol. 2025 Nov 03; 36(1):42. de Mestier L, Halfdanarson TR, Apostolidis L, Koumarianou A, Hernando J, Riechelmann R, Bergsland EK, Cingarlini S, Shaheen S, Crona J, Kreutzfeldt S, Mosalem O, Al-Toubah T, Cros J, Strosberg JR. PMID: 41182464.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansCells
  3. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202). J Clin Oncol. 2025 Oct 10; 43(29):3170-3183. Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA. PMID: 40902132; PMCID: PMC12457709.
    View in: PubMed Mentions: Fields:
  4. 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning. Med Phys. 2025 Aug; 52(8):e18069. Miao X, Su P, Ohliger MA, Yang Y, Pang J, Hotca AE, Hope TA, Hong CW, Bergsland EK, Feng M, Scholey JE. PMID: 40903915; PMCID: PMC12409090.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  5. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study. Ther Adv Med Oncol. 2025; 17:17588359251356335. Riechelmann RP, Torrezan GT, Bergsland E, Raj N, Strosberg J, Moon F, Felismino TC, Knappskog S, Trevizani E, Cingarlini S, Sorbye H. PMID: 40727887; PMCID: PMC12301599.
    View in: PubMed Mentions:
  6. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer. 2025 Jul 01; 131(13):e35871. Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies Consortium Group. PMID: 40558053.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  7. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms. Ann Surg Oncol. 2025 Jun 25. Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies (PSM) Consortium Group. PMID: 40560496.
    View in: PubMed Mentions: 1 Fields:
  8. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncol Pract. 2026 Jan; 22(1):19-35. Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM, Dasari AN, Gangi A, Clarke CN, Hallet J, Howe JR, Grady E, Ivanidze J, Mittra ES, White SB, Raj NP, Vijayvergia N, Lewis MA, Chan JA, Kunz PL, Mailman J, Arshad J, Soares HP, Singh S, Chandrasekharan C, Soulen MC, Janson ET, Halfdanarson TR, Strosberg JR, Bergsland EK. PMID: 40344544.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  9. Appropriate use of tissue sampling and somatostatin receptor PET imaging in the diagnosis of pancreatic neuroendocrine tumors: results of an International Delphi Consensus. Surg Endosc. 2025 Jun; 39(6):3435-3446. Casey M, Tozzi F, Wang J, Park KM, Bergsland E, Hope T, Kennecke HF, Rose JB, Babicky M, Irani SS, El-Hayek KM, Hilal MA, Asbun HJ, Cleary S, Smeets P, Berrevoet F, Adam M, Rashidian N, Alseidi A, PNET Diagnosis Research Group. PMID: 40316747; PMCID: PMC12116717.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  10. Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study. AJR Am J Roentgenol. 2025 07; 225(1):e2532888. Hong CW, Yang Y, Remick I, Su P, Itriago-Leon P, Nickel MD, Fautz HP, Majeed W, Bergsland E, Hope TA, Ohliger MA. PMID: 40237428.
    View in: PubMed Mentions: Fields:
  11. Metastatic insulinoma-outcomes in the current era. Oncologist. 2025 Mar 10; 30(3). Masharani U, Lindsay S, Moon F, Paciorek A, Bergsland E. PMID: 39475415; PMCID: PMC11954510.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  12. Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation Modeling. J Natl Compr Canc Netw. 2025 Feb; 23(2):27-32. Paciorek A, Mulvey C, McKinley M, Zhang L, Cheng I, Moon F, Le BK, Shih BE, Whitman J, Bergsland E. PMID: 39938473.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  13. Factors associated with grade progression in pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2025 Mar 01; 32(3). Wang SJ, Kidder W, Joseph NM, Le BK, Lindsay S, Moon F, Nakakura EK, Zhang L, Bergsland EK. PMID: 39813097; PMCID: PMC11968147.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  14. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocr Pathol. 2024 Dec; 35(4):325-337. Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S. PMID: 39556303; PMCID: PMC11659342.
    View in: PubMed Mentions: 17 Fields:
    Translation:Humans
  15. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies. JCO Precis Oncol. 2024 Nov; 8:e2400328. Tsang ES, Aggarwal RR, Bergsland EK, Calabrese S, Rozie A, Chaudhuri S, Dhawan MS, Pawlowska N, Grabowsky J, Thomas S, Munster PN. PMID: 39509670.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansCTClinical Trials
  16. Withdrawal pain following patients discontinuing Trk inhibitors. J Oncol Pharm Pract. 2025 Jan; 31(1):147-150. Chin A, Lindsay S, Bergsland EK, Kang H. PMID: 39191376; PMCID: PMC11771077.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  17. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801. Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P, Aggarwal RR. PMID: 38920407; PMCID: PMC11264598.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCTClinical Trials
  18. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024 Jun; 8:e2300494. Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. PMID: 38865673.
    View in: PubMed Mentions: 4 Fields:
    Translation:HumansCTClinical Trials
  19. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. Ann Surg Oncol. 2024 Sep; 31(9):5507-5514. Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK. PMID: 38797790; PMCID: PMC11300575.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  20. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2024 Jul-Aug; 74(4):359-367. Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. PMID: 38685134; PMCID: PMC11938941.
    View in: PubMed Mentions: 32 Fields:
    Translation:Humans
  21. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center. Oncologist. 2024 Mar 04; 29(3):e351-e359. Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K. PMID: 37440206; PMCID: PMC10911925.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansPHPublic Health
  22. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy. J Nucl Med. 2024 03 01; 65(3):409-415. Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA. PMID: 38428966; PMCID: PMC11927066.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  23. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors. Endocr Relat Cancer. 2024 01 01; 31(1). Mulvey CK, Paciorek A, Moon F, Steiding P, Shih B, Gubens MA, Zhang L, Bergsland EK, Cheng I. PMID: 37882324; PMCID: PMC10762535.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  24. The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study. Surgery. 2024 01; 175(1):80-89. Sada A, Foster TR, Al-Ward R, Sawani S, Charchar H, Pishdad R, Ben-Shlomo A, Dy BM, Lyden ML, Bergsland E, Jasim S, Raj N, Shank JB, Hamidi O, Hamrahian AH, Chambô JL, Srougi V, Fragoso MC, Graham PH, Habra MA, Bancos I, McKenzie TJ. PMID: 37945477.
    View in: PubMed Mentions: 10 Fields:
    Translation:Humans
  25. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol. 2023 11 10; 41(32):5049-5067. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. PMID: 37774329.
    View in: PubMed Mentions: 52 Fields:
    Translation:Humans
  26. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 09 07; 115(9):1001-1010. Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL, NET CTPM participants . PMID: 37255328; PMCID: PMC10483264.
    View in: PubMed Mentions: 6 Fields:
    Translation:Humans
  27. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow. J Med Internet Res. 2023 08 21; 25:e47784. Majmudar S, Graff SL, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S. PMID: 37603399; PMCID: PMC10477917.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansPHPublic Health
  28. Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel). 2023 Jul 21; 15(14). Varghese DG, Del Rivero J, Bergsland E. PMID: 37509373; PMCID: PMC10378410.
    View in: PubMed Mentions: 11
  29. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer. 2023 08 01; 30(8). Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. PMID: 37184955; PMCID: PMC10388681.
    View in: PubMed Mentions: 24 Fields:
    Translation:Humans
  30. Preclinical Models of Adrenocortical Cancer. Cancers (Basel). 2023 May 23; 15(11). Sedlack AJH, Hatfield SJ, Kumar S, Arakawa Y, Roper N, Sun NY, Nilubol N, Kiseljak-Vassiliades K, Hoang CD, Bergsland EK, Hernandez JM, Pommier Y, Del Rivero J. PMID: 37296836; PMCID: PMC10251941.
    View in: PubMed Mentions: 7
  31. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. Br J Cancer. 2023 08; 129(2):291-300. Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. PMID: 37208512; PMCID: PMC10338510.
    View in: PubMed Mentions: 4 Fields:
    Translation:HumansCTClinical Trials
  32. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. J Neuroendocrinol. 2023 04; 35(4):e13260. Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK. PMID: 37002881.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  33. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. Clin Genitourin Cancer. 2023 06; 21(3):403-414.e5. Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR. PMID: 37031047; PMCID: PMC11296333.
    View in: PubMed Mentions: 7 Fields:
    Translation:Humans
  34. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis. Eur J Cancer. 2023 03; 182:43-52. Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A. PMID: 36738541; PMCID: PMC10230159.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  35. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap. Mod Pathol. 2023 03; 36(3):100065. Umetsu SE, Kakar S, Basturk O, Kim GE, Chatterjee D, Wen KW, Hale G, Shafizadeh N, Cho SJ, Whitman J, Gill RM, Jones KD, Navale P, Bergsland E, Klimstra D, Joseph NM. PMID: 36788102.
    View in: PubMed Mentions: 23 Fields:
    Translation:Humans
  36. Preclinical Models of Neuroendocrine Neoplasia. Cancers (Basel). 2022 Nov 17; 14(22). Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J. PMID: 36428741; PMCID: PMC9688518.
    View in: PubMed Mentions: 8
  37. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022 11 03; 27(11):940-951. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. PMID: 35983951; PMCID: PMC9632312.
    View in: PubMed Mentions: 45 Fields:
    Translation:Humans
  38. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Res Commun. 2022 07; 2(7):570-576. Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. PMID: 36923283; PMCID: PMC10010328.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCTClinical Trials
  39. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol. 2022 08 20; 40(24):2818-2829. Hope TA, Pavel M, Bergsland EK. PMID: 35649195; PMCID: PMC9390818.
    View in: PubMed Mentions: 21 Fields:
    Translation:Humans
  40. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung. JCO Precis Oncol. 2022 06; 6:e2200009. Sun F, Grenert JP, Tan L, Van Ziffle J, Joseph NM, Mulvey CK, Bergsland E. PMID: 35737914; PMCID: PMC9249272.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  41. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. Abdom Radiol (NY). 2022 12; 47(12):3962-3970. Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M. PMID: 35244755; PMCID: PMC12285572.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  42. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022 03 10; 40(8):892-910. Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. PMID: 34936379.
    View in: PubMed Mentions: 154 Fields:
    Translation:Humans
  43. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. Biosens Bioelectron. 2022 Mar 01; 199:113854. Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP. PMID: 34896918; PMCID: PMC8900541.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansCells
  44. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. Pancreatology. 2022 Jan; 22(1):123-129. Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S. PMID: 34736838.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  45. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. Oncologist. 2021 11; 26(11):950-955. Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. PMID: 34342086; PMCID: PMC8571741.
    View in: PubMed Mentions: 21 Fields:
    Translation:Humans
  46. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 07 28; 19(7):839-868. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. PMID: 34340212.
    View in: PubMed Mentions: 323 Fields:
    Translation:Humans
  47. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PLoS One. 2021; 16(6):e0252574. Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M. PMID: 34077464; PMCID: PMC8171937.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  48. The Immunotherapy Landscape in Adrenocortical Cancer. Cancers (Basel). 2021 May 28; 13(11). Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J. PMID: 34071333; PMCID: PMC8199088.
    View in: PubMed Mentions: 12
  49. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Neuroendocrinology. 2022; 112(3):298-310. Hörsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Öberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH. PMID: 33940581; PMCID: PMC8985007.
    View in: PubMed Mentions: 5 Fields:
    Translation:Humans
  50. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas. 2021 04 01; 50(4):506-512. Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K. PMID: 33939661; PMCID: PMC8097723.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  51. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors. J Gastrointest Surg. 2021 11; 25(11):2954-2956. Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK. PMID: 33742361.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  52. Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms. Endocr Relat Cancer. 2021 Mar; 28(3):161-172. Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. PMID: 33480358.
    View in: PubMed Mentions: 51 Fields:
  53. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer. 2021 Mar; 52(1):212-221. Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. PMID: 32146619; PMCID: PMC7714089.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCTClinical Trials
  54. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis. J Nucl Med. 2021 Sep 01; 62(9):1285-1291. Whitman J, Allen IE, Bergsland EK, Suh I, Hope TA. PMID: 33452040; PMCID: PMC8882892.
    View in: PubMed Mentions: 17 Fields:
    Translation:Humans
  55. Carcinoid Crisis-Induced Acute Systolic Heart Failure. JACC Case Rep. 2020 Nov; 2(13):2068-2071. Maddali MV, Chiu C, Cedarbaum ER, Yogeswaran V, Seedahmed M, Smith W, Bergsland E, Fidelman N, Kennedy JLW. PMID: 34317110; PMCID: PMC8299771.
    View in: PubMed Mentions: 1
  56. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. Abdom Radiol (NY). 2022 09; 47(9):3078-3100. Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC. PMID: 33095312.
    View in: PubMed Mentions: 20 Fields:
    Translation:Humans
  57. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020 08; 49(7):863-881. Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. PMID: 32675783.
    View in: PubMed Mentions: 86 Fields:
    Translation:Humans
  58. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. J Thorac Oncol. 2020 10; 15(10):1577-1598. Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. PMID: 32663527.
    View in: PubMed Mentions: 55 Fields:
    Translation:Humans
  59. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas. 2020 07; 49(6):723-728. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. PMID: 32433264; PMCID: PMC7253037.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCellsPHPublic Health
  60. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns? J Nucl Med. 2020 Aug; 61(8):1094-1095. Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, Pavel M, Reidy-Lagunes D, Siveke J, Strosberg J, Dittmer U, Herrmann K. PMID: 32576637; PMCID: PMC7413236.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansPHPublic Health
  61. Reply to S. Boutayeb et al. JCO Oncol Pract. 2020 08; 16(8):525. Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. PMID: 32574129.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansCells
  62. Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. J Nucl Med. 2021 02; 62(2):221-227. Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, Lindsay S, Bergsland EK, Hope TA. PMID: 32513903.
    View in: PubMed Mentions: 15 Fields:
    Translation:HumansCTClinical Trials
  63. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. JCO Oncol Pract. 2020 07; 16(7):383-388. Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY. PMID: 32352884; PMCID: PMC12958309.
    View in: PubMed Mentions: 16 Fields:
    Translation:HumansCellsPHPublic Health
  64. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer. 2020 07 01; 126(13):3021-3030. Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K, Piha-Paul SA. PMID: 32320048.
    View in: PubMed Mentions: 89 Fields:
    Translation:HumansCTClinical Trials
  65. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors. J Surg Oncol. 2020 Aug; 122(2):204-211. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. PMID: 32291778.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  66. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res. 2020 05 01; 26(9):2124-2130. Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J. PMID: 31980466; PMCID: PMC7811789.
    View in: PubMed Mentions: 114 Fields:
    Translation:HumansCTClinical Trials
  67. A Rare Case of Carcinoid Constrictive Pericarditis. JACC Case Rep. 2020 Jan; 2(1):1-5. Wang TS, Bergsland EK, Zhang R, Ihnken K, Tolstrup K. PMID: 34316954; PMCID: PMC8301495.
    View in: PubMed Mentions:
  68. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. J Surg Oncol. 2020 Feb; 121(2):330-336. Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK. PMID: 31828813.
    View in: PubMed Mentions: 6 Fields:
  69. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. PMID: 30058032; PMCID: PMC6650370.
    View in: PubMed Mentions: 14 Fields:
    Translation:Humans
  70. Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma. JCO Precis Oncol. 2019 Dec; 3:1-7. Whitman J, Kardosh A, Diaz L, Fong L, Hope T, Onodera C, Joseph N, Le D, Fisher G, Bergsland E. PMID: 35100735.
    View in: PubMed Mentions: 4 Fields:
  71. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. J Patient Rep Outcomes. 2019 Oct 26; 3(1):64. Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P. PMID: 31655936; PMCID: PMC6815313.
    View in: PubMed Mentions: 3 Fields:
  72. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors. J Surg Oncol. 2019 Dec; 120(8):1311-1317. Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK. PMID: 31613999.
    View in: PubMed Mentions: 5 Fields:
    Translation:Humans
  73. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors. Pancreas. 2019 08; 48(7):948-952. Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, Hope TA. PMID: 31268975.
    View in: PubMed Mentions: 10 Fields:
    Translation:Humans
  74. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma. PLoS One. 2019; 14(7):e0219469. Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS. PMID: 31291332; PMCID: PMC6620013.
    View in: PubMed Mentions: 5 Fields:
    Translation:Humans
  75. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 06 01; 37(16):1436-1447. Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N. PMID: 30986117.
    View in: PubMed Mentions: 42 Fields:
    Translation:Humans
  76. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases. Pancreas. 2019 04; 48(4):496-503. Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K. PMID: 30946246.
    View in: PubMed Mentions: 13 Fields:
    Translation:Humans
  77. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist. 2019 08; 24(8):e662-e670. Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. PMID: 30651397; PMCID: PMC6693702.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  78. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. Transl Oncol. 2019 Mar; 12(3):550-560. Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS. PMID: 30639964; PMCID: PMC6328378.
    View in: PubMed Mentions: 1
  79. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist. 2019 08; 24(8):1066-1075. Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. PMID: 30610008; PMCID: PMC6693720.
    View in: PubMed Mentions: 7 Fields:
    Translation:Humans
  80. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist. 2019 08; 24(8):1056-1065. Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. PMID: 30606883; PMCID: PMC6693731.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  81. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018 11 01; 4(11):1597-1604. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E, Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. PMID: 30054622.
    View in: PubMed Mentions: 34 Fields:
    Translation:Humans
  82. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 12; 17(12):2702-2709. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. PMID: 30254185; PMCID: PMC6279485.
    View in: PubMed Mentions: 24 Fields:
    Translation:HumansAnimalsCells
  83. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. Mod Pathol. 2019 02; 32(2):290-305. Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM. PMID: 30237525.
    View in: PubMed Mentions: 28 Fields:
    Translation:Humans
  84. Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors. J Oncol Pract. 2018 08; 14(8):487-489. Mulvey CK, Bergsland EK. PMID: 30096272.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  85. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 06; 16(6):693-702. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. PMID: 29891520.
    View in: PubMed Mentions: 153 Fields:
    Translation:Humans
  86. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clin Ther. 2018 06; 40(6):952-962.e2. Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. PMID: 29724499.
    View in: PubMed Mentions: 14 Fields:
    Translation:HumansCTClinical Trials
  87. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. Clin Ther. 2017 Nov; 39(11):2158-2168. Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. PMID: 29074312.
    View in: PubMed Mentions: 27 Fields:
    Translation:Humans
  88. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018 01; 59(1):66-74. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. PMID: 29025982; PMCID: PMC6910630.
    View in: PubMed Mentions: 126 Fields:
    Translation:Humans
  89. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Fam Cancer. 2017 10; 16(4):537-543. Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. PMID: 28283864.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  90. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017 07; 46(6):715-731. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. PMID: 28609357; PMCID: PMC5502737.
    View in: PubMed Mentions: 149 Fields:
    Translation:Humans
  91. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 07; 46(6):707-714. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. PMID: 28609356; PMCID: PMC5642985.
    View in: PubMed Mentions: 139 Fields:
    Translation:Humans
  92. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist. 2017 07; 22(7):768-773. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. PMID: 28507205; PMCID: PMC5507651.
    View in: PubMed Mentions: 23 Fields:
    Translation:Humans
  93. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Med Oncol. 2017 May; 34(5):88. Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E. PMID: 28393314.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  94. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017; 5:22. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. PMID: 28344808; PMCID: PMC5360066.
    View in: PubMed Mentions: 178 Fields:
    Translation:HumansCellsCTClinical Trials
  95. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas. 2017 03; 46(3):416-426. Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK. PMID: 28187108.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  96. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. PMID: 28078110; PMCID: PMC5177572.
    View in: PubMed Mentions: 14
  97. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 11; 45(10):1394-1400. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. PMID: 27171514.
    View in: PubMed Mentions: 29 Fields:
    Translation:HumansCTClinical Trials
  98. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan; 35(1):14-23. Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. PMID: 27918724.
    View in: PubMed Mentions: 121 Fields:
    Translation:HumansCTClinical Trials
  99. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 05; 23(5):411-8. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. PMID: 27080472; PMCID: PMC4963225.
    View in: PubMed Mentions: 26 Fields:
    Translation:HumansCTClinical Trials
  100. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. Ann Surg Oncol. 2016 08; 23(8):2548-55. Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J. PMID: 27020587; PMCID: PMC5047012.
    View in: PubMed Mentions: 60 Fields:
    Translation:HumansCTClinical Trials
  101. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30(1):63-82. Mulvey CK, Bergsland EK. PMID: 26614369.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  102. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9. Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. PMID: 26603258.
    View in: PubMed Mentions: 56 Fields:
    Translation:HumansCTClinical Trials
  103. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging. EJNMMI Phys. 2015 Dec; 2(1):21. Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK. PMID: 26501822; PMCID: PMC4573645.
    View in: PubMed Mentions: 8
  104. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015 Aug; 40(6):1432-40. Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. PMID: 25820755.
    View in: PubMed Mentions: 38 Fields:
    Translation:Humans
  105. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma. Cancer. 2015 Oct 01; 121(19):3481-90. Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN. PMID: 26177599; PMCID: PMC4832308.
    View in: PubMed Mentions: 48 Fields:
    Translation:HumansCTClinical Trials
  106. Transcatheter pulmonic valve replacement in carcinoid heart disease. Eur Heart J Cardiovasc Imaging. 2015 Sep; 16(9):1046. Heidecker B, Moore P, Bergsland EK, Merrick SH, Rao RK. PMID: 26003151.
    View in: PubMed Mentions: 6 Fields:
    Translation:Humans
  107. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 2015 Apr 28; 11(4):577-91. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. PMID: 25892230; PMCID: PMC4438771.
    View in: PubMed Mentions: 94 Fields:
    Translation:HumansAnimalsCells
  108. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts? J Clin Oncol. 2015 May 10; 33(14):1523-6. Bergsland EK. PMID: 25646187.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  109. Is more not better?: combination therapies in colorectal cancer treatment. Hematol Oncol Clin North Am. 2015 Feb; 29(1):85-116. Bergsland EK. PMID: 25475574.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  110. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015; 92-103. Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. PMID: 25993147.
    View in: PubMed Mentions: 25 Fields:
    Translation:Humans
  111. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015 Jan; 13(1):78-108. Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D, National comprehensive cancer network. PMID: 25583772.
    View in: PubMed Mentions: 173 Fields:
    Translation:Humans
  112. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect. 2015 Mar; 4(1):9-17. Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK. PMID: 25430999; PMCID: PMC4285767.
    View in: PubMed Mentions: 41
  113. Neuroendocrine tumors of unknown primary: is the primary site really not known? JAMA Surg. 2014 Sep; 149(9):889-90. Bergsland EK, Nakakura EK. PMID: 25029597.
    View in: PubMed Mentions: 9 Fields:
    Translation:Humans
  114. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014 Oct; 21(5):705-14. Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A. PMID: 25012985; PMCID: PMC4295770.
    View in: PubMed Mentions: 51 Fields:
    Translation:Humans
  115. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell. 2014 Jun 16; 25(6):809-821. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM. PMID: 24909985; PMCID: PMC4063283.
    View in: PubMed Mentions: 175 Fields:
    Translation:HumansAnimalsCells
  116. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. PMID: 24448917.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansCTClinical Trials
  117. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol. 2014 Apr; 73(4):695-702. Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK. PMID: 24488322.
    View in: PubMed Mentions: 15 Fields:
    Translation:HumansCTClinical Trials
  118. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191; PMCID: PMC3790192.
    View in: PubMed Mentions: 18 Fields:
    Translation:HumansCellsCTClinical Trials
  119. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. PMID: 23542178; PMCID: PMC3982880.
    View in: PubMed Mentions: 58 Fields:
    Translation:HumansAnimalsCells
  120. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-1907. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998; PMCID: PMC3690907.
    View in: PubMed Mentions: 32 Fields:
    Translation:HumansCellsCTClinical Trials
  121. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):1-3. Bergsland EK. PMID: 23391108.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  122. The evolving landscape of neuroendocrine tumors. Semin Oncol. 2013 Feb; 40(1):4-22. Bergsland EK. PMID: 23391109.
    View in: PubMed Mentions: 11 Fields:
    Translation:Humans
  123. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. PMID: 21552099.
    View in: PubMed Mentions: 4 Fields:
    Translation:HumansCTClinical Trials
  124. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients. Pancreas. 2012 Aug; 41(6):840-4. Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK. PMID: 22781907.
    View in: PubMed Mentions: 38 Fields:
    Translation:Humans
  125. Systemic therapy for advanced carcinoid tumors: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 01; 10(6):785-93. Paulson AS, Bergsland EK. PMID: 22679120.
    View in: PubMed Mentions: 10 Fields:
    Translation:Humans
  126. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):724-64. Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA, National Comprehensive Cancer Networks. PMID: 22679117.
    View in: PubMed Mentions: 86 Fields:
    Translation:Humans
  127. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. PMID: 22270257.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCells
  128. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011 Jul; 254(1):97-102. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM, Timing of Rectal Cancer Response to Chemoradiation Consortium. PMID: 21494121; PMCID: PMC3115473.
    View in: PubMed Mentions: 137 Fields:
    Translation:HumansCTClinical Trials
  129. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011 Mar 01; 29(7):934-43. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. PMID: 21263089; PMCID: PMC3068065.
    View in: PubMed Mentions: 133 Fields:
    Translation:Humans
  130. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res. 2010 Sep; 163(1):47-51. Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK. PMID: 20599218.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  131. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar; 145(3):276-80. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK. PMID: 20231629.
    View in: PubMed Mentions: 61 Fields:
    Translation:Humans
  132. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer. 2010 Mar; 17(1):283-91. Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK. PMID: 20048018.
    View in: PubMed Mentions: 11 Fields:
    Translation:HumansAnimalsCells
  133. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
    View in: PubMed Mentions: 37 Fields:
    Translation:HumansCTClinical Trials
  134. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med. 2009 Jan 08; 360(2):195-7. Kulke MH, Bergsland EK, Yao JC. PMID: 19129539.
    View in: PubMed Mentions: 65 Fields:
    Translation:Humans
  135. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer. 2009 Mar; 16(1):267-79. Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK. PMID: 18987169.
    View in: PubMed Mentions: 21 Fields:
    Translation:HumansAnimalsCells
  136. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. PMID: 18815548.
    View in: PubMed Mentions: 37 Fields:
    Translation:HumansCells
  137. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008 Jul 10; 26(20):3403-10. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS. PMID: 18612155.
    View in: PubMed Mentions: 204 Fields:
  138. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. PMID: 18379729.
    View in: PubMed Mentions: 31 Fields:
    Translation:HumansCTClinical Trials
  139. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 18181045.
    View in: PubMed Mentions: 9 Fields:
    Translation:HumansCTClinical Trials
  140. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. Clin Colorectal Cancer. 2008 Jan; 7(1):44-7. Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L. PMID: 18279576.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCTClinical Trials
  141. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007 Oct 20; 25(30):4793-9. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ. PMID: 17947727.
    View in: PubMed Mentions: 56 Fields:
    Translation:HumansCTClinical Trials
  142. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007 Aug 15; 99(16):1232-9. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H. PMID: 17686822.
    View in: PubMed Mentions: 315 Fields:
    Translation:Humans
  143. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer? Surg Oncol Clin N Am. 2007 Jul; 16(3):639-51, x. Nakakura EK, Venook AP, Bergsland EK. PMID: 17606198.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  144. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematol Oncol Clin North Am. 2007 Jun; 21(3):457-73; viii. Nakakura EK, Bergsland EK. PMID: 17548034.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  145. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. PMID: 17363191.
  146. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 01; 24(22):3555-61. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. PMID: 16877721.
    View in: PubMed Mentions: 58 Fields:
    Translation:HumansCTClinical Trials
  147. Pancreatoblastoma in an adult: case report and review of the literature. J Gastrointest Surg. 2006 Jun; 10(6):829-36. Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK. PMID: 16769539.
    View in: PubMed Mentions: 11 Fields:
    Translation:Humans
  148. Targeting growth factors and angiogenesis; using small molecules in malignancy. Cancer Metastasis Rev. 2006 Jun; 25(2):279-92. Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H. PMID: 16770540.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansAnimalsCells
  149. When does the presence of the target predict response to the targeted agent? J Clin Oncol. 2006 Jan 10; 24(2):213-6. Bergsland EK. PMID: 16365177.
    View in: PubMed Mentions: 8 Fields:
    Translation:Humans
  150. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 16344320.
    View in: PubMed Mentions: 14 Fields:
    Translation:HumansCTClinical Trials
  151. Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol. 2005 Sep; 6(5):411-21. Whisenant J, Bergsland E. PMID: 16107244.
    View in: PubMed Mentions: 9 Fields:
    Translation:Humans
  152. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. PMID: 15999098; PMCID: PMC2361548.
    View in: PubMed Mentions: 59 Fields:
    Translation:HumansCTClinical Trials
  153. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun 01; 23(16):3706-12. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. PMID: 15867200.
    View in: PubMed Mentions: 195 Fields:
    Translation:HumansCTClinical Trials
  154. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer. Clin Cancer Res. 2005 Mar 01; 11(5):1791-7. Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM. PMID: 15756001.
    View in: PubMed Mentions: 12 Fields:
    Translation:HumansCells
  155. Update on clinical trials targeting vascular endothelial growth factor in cancer. Am J Health Syst Pharm. 2004 Nov 01; 61(21 Suppl 5):S12-20. Bergsland EK. PMID: 15552622.
    View in: PubMed Mentions: 11 Fields:
    Translation:Humans
  156. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm. 2004 Nov 01; 61(21 Suppl 5):S4-11. Bergsland EK. PMID: 15552621.
    View in: PubMed Mentions: 7 Fields:
    Translation:Humans
  157. Angiogenesis in colorectal cancer: therapeutic implications and future directions. Hematol Oncol Clin North Am. 2004 Oct; 18(5):1087-119, ix. Allen J, Bergsland EK. PMID: 15474337.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  158. Maximizing the potential of bevacizumab in cancer treatment. Oncologist. 2004; 9 Suppl 1:36-42. Bergsland E, Dickler MN. PMID: 15178814.
    View in: PubMed Mentions: 25 Fields:
    Translation:Humans
  159. Couples therapy at end of life. Psychooncology. 2003 Sep; 12(6):620-7. Mohr DC, Moran PJ, Kohn C, Hart S, Armstrong K, Dias R, Bergsland E, Folkman S. PMID: 12923802.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCTClinical Trials
  160. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003 May; 111(9):1287-95. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. PMID: 12727920; PMCID: PMC154450.
    View in: PubMed Mentions: 456 Fields:
    Translation:AnimalsCells
  161. Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med. 2003 Apr 21; 197(8):1017-28. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D. PMID: 12695493; PMCID: PMC2193878.
    View in: PubMed Mentions: 57 Fields:
    Translation:HumansAnimalsCells
  162. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Jan 01; 21(1):60-5. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. PMID: 12506171.
    View in: PubMed Mentions: 444 Fields:
    Translation:HumansCTClinical Trials
  163. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):192-6. Ko AH, Bergsland EK, Lee GA. PMID: 12645810.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  164. Shedding old paradigms: developing viruses to treat cancer. J Clin Oncol. 2002 May 01; 20(9):2220-2. Bergsland EK, Venook AP. PMID: 11980991.
    View in: PubMed Mentions: Fields:
    Translation:HumansCells
  165. Molecular mechanisms underlying the development of hepatocellular carcinoma. Semin Oncol. 2001 Oct; 28(5):521-31. Bergsland EK. PMID: 11685745.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansAnimals
  166. Hepatocellular carcinoma. Curr Opin Oncol. 2000 Jul; 12(4):357-61. Bergsland EK, Venook AP. PMID: 10888422.
    View in: PubMed Mentions: 12 Fields:
    Translation:HumansAnimals
  167. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000 Apr; 105(8):1045-7. Hanahan D, Bergers G, Bergsland E. PMID: 10772648; PMCID: PMC300842.
    View in: PubMed Mentions: 257 Fields:
    Translation:HumansAnimalsCells
  168. Human acellular dermal matrix as a novel model of malignant epithelial cell invasion. Invasion Metastasis. 1997; 17(1):42-52. Bullard KM, Banda MJ, Arbeit JM, Bergsland E, Young DM. PMID: 9425323.
    View in: PubMed Mentions: 3 Fields:
    Translation:HumansAnimalsCells

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs